These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Current Immunotherapies for Glioblastoma Multiforme. Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H Front Immunol; 2020; 11():603911. PubMed ID: 33767690 [TBL] [Abstract][Full Text] [Related]
4. Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives. Cuoco JA; Benko MJ; Busch CM; Rogers CM; Prickett JT; Marvin EA World Neurosurg; 2018 Dec; 120():302-315. PubMed ID: 30196171 [TBL] [Abstract][Full Text] [Related]
5. Current Advances in Immunotherapy for Glioblastoma. Mende AL; Schulte JD; Okada H; Clarke JL Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872 [TBL] [Abstract][Full Text] [Related]
6. Current challenges in designing GBM trials for immunotherapy. Weathers SP; Gilbert MR J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401 [TBL] [Abstract][Full Text] [Related]
7. Cellular-based immunotherapies for patients with glioblastoma multiforme. Xu X; Stockhammer F; Schmitt M Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for the treatment of glioblastoma. Thomas AA; Ernstoff MS; Fadul CE Cancer J; 2012; 18(1):59-68. PubMed ID: 22290259 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in human glioblastoma. Szabo AT; Carpentier AF Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075 [TBL] [Abstract][Full Text] [Related]
10. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?]. Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303 [TBL] [Abstract][Full Text] [Related]
11. Advances in Immunotherapy for Glioblastoma Multiforme. Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344 [TBL] [Abstract][Full Text] [Related]
12. Vaccine for aggressive brain tumors may prolong survival. Health News; 2004 Dec; 10(12):7. PubMed ID: 15645564 [No Abstract] [Full Text] [Related]
14. Current vaccine trials in glioblastoma: a review. Xu LW; Chow KK; Lim M; Li G J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271 [TBL] [Abstract][Full Text] [Related]
15. Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. Datsi A; Sorg RV Front Immunol; 2021; 12():770390. PubMed ID: 34795675 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Glioblastoma: Current Progress and Challenges. Yu MW; Quail DF Front Immunol; 2021; 12():676301. PubMed ID: 34054867 [TBL] [Abstract][Full Text] [Related]
18. The Safety of available immunotherapy for the treatment of glioblastoma. Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218 [TBL] [Abstract][Full Text] [Related]
19. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV Trials; 2018 May; 19(1):293. PubMed ID: 29801515 [TBL] [Abstract][Full Text] [Related]
20. Vaccination in the immunotherapy of glioblastoma. Kong Z; Wang Y; Ma W Hum Vaccin Immunother; 2018 Feb; 14(2):255-268. PubMed ID: 29087782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]